{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-54352","upperLimit":"0","value":"-14518"},{"groupId":"OG001","lowerLimit":"-66","upperLimit":"0","value":"-12.5"},{"groupId":"OG002","lowerLimit":"28","upperLimit":"28","value":"28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"End of cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-55116","upperLimit":"0","value":"-4517"},{"groupId":"OG001","lowerLimit":"-88","upperLimit":"49","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-282977","upperLimit":"0","value":"-55116"},{"groupId":"OG001","lowerLimit":"-88","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"-88","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1)","id":"OG000","title":"Phase I: VR-DA-EPOCH, Dose Level 1"},{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2)","id":"OG001","title":"Phase I: VR-DA-EPOCH, Dose Level 2"},{"description":"Phase I, Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.","id":"OG002","title":"Phase I: VR-CHOP, Dose Level 1"}],"paramType":"MEDIAN","populationDescription":"Eligible participants who returned for follow-up with evaluable data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)","type":"SECONDARY","unitOfMeasure":"copies per milliliter"}